-
1Academic Journal
Συγγραφείς: M. Yu. Maksimova, A. S. Airapetova, М. Ю. Максимова, А. С. Айрапетова
Συνεισφορές: The investigation has been conducted within the framework of the government program for the Federal State Budgetary Scientific Institution «Scientific Center of Neurology»., Работа выполнена в рамках государственного задания ФГБНУ «Научный центр неврологии».
Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 14, No 3 (2022); 81-86 ; Неврология, нейропсихиатрия, психосоматика; Vol 14, No 3 (2022); 81-86 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2022-3
Θεματικοί όροι: вторичная профилактика ишемического инсульта, non-cardioembolic stroke, secondary prevention of ischemic stroke, некардиоэмболический инсульт
Περιγραφή αρχείου: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1828/1420; GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):439-58. doi:10.1016/S1474-4422(19)30034-1. Epub 2019 Mar 11.; Flach C, Muruet W, Wolfe CDA, et al. Risk and Secondary Prevention of Stroke Recurrence: A Population-Base Cohort Study. Stroke. 2020 Aug;51(8):2435-44. doi:10.1161/STROKEAHA.120.028992. Epub 2020 Jul 10.; Парфенов ВА, Вербицкая СВ. Антитромбоцитарная терапия во вторичной профилактике ишемического инсульта. Медицинский совет. 2015;(5):6-13. doi:10.21518/2079-701X-2015-5-6-13; Парфенов ВА, Вербицкая СВ. Профилактика повторного некардиоэмболического ишемического инсульта на основе антитромбоцитарных средств. Атеротромбоз. 2016;(2):89-97. doi:10.21518/2307-1109-2016-2-89-97; Пирадов МА, Танашян ММ, Максимова МЮ, редакторы. Инсульт: cовременные технологии диагностики и лечения: Руководство для врачей. Москва: МЕДпресс-информ; 2018. 360 с.; Домашенко МА, Максимова МЮ, Танашян ММ. Современный взгляд на назначение антиагрегантных препаратов для вторичной профилактики некардиоэмболического ишемического инсульта. Эффективная фармакотерапия. 2018;24:82-6.; Суслина ЗА, Высоцкая ВГ. Антиагрегационное действие и клинический эффект малых доз аспирина при лечении больных с цереброваскулярной патологией на фоне артериальной гипертензии. Клиническая медицина. 1983;6(9):51-9.; International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 1997 May 31;349(9065):1569-81.; CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997 Jun 7;349(9066):1641-9.; Antithrombotic Trialists' (ATT) Collaboration; Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 May 30;373(9678):1849-60. doi:10.1016/S0140-6736(09)60503-1; Goyan JE. The “trials” of a long-term clinical trial: the Ticlopidine Aspirin Stroke Study and the Canadian-American Ticlopidine Study. Control Clin Trials. 1989;10(4 Suppl):236S-244S. doi:10.1016/0197-2456(89)90062-7; CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329-39. doi:10.1016/s0140-6736(96)09457-3; Diener HC, Bogousslavsky J, Brass LM, et al; MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331-7. doi:10.1016/S0140-6736(04)16721-4; Bhatt DL, Flather MD, Hacke W, et al; CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007 May 15;49(19):1982-8. doi:10.1016/j.jacc.2007.03.025. Epub 2007 Apr 11.; Wang Y, Pan Y, Zhao X, et al; CHANCE Investigators. Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes. Circulation. 2015 Jul 7;132(1):40-6. doi:10.1161/CIRCULATIONAHA.114.014791. Epub 2015 May 8.; Amarenco P, Albers GW, Denison H, et al; SOCRATES Steering Committee and Investigators. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol. 2017 Apr;16(4):301-10. doi:10.1016/S1474-4422(17)30038-8. Epub 2017 Feb 23.; Johnston SC, Amarenco P, Denison H, et al; THALES Investigators. The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and Aspirin for Prevention of Stroke and Death (THALES) trial: Rationale and design. Int J Stroke. 2019 Oct;14(7):745-51. doi:10.1177/1747493019830307. Epub 2019 Feb 12.; Best LC, McGuire MB, Jones PB, et al. Mode of action of dipyridamole on human platelets. Thromb Res. 1979;16(3-4):367-79. doi:10.1016/0049-3848(79)90084-7; Wang C, Lin W, Playa H, et al. Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochem Pharmacol. 2013 Dec 1;86(11):1531-40. doi:10.1016/j.bcp.2013.08.063. Epub 2013 Sep 7.; Dresse A, Chevolet C, Delapierre D, et al. Pharmacokinetics of oral dipyridamole (Persantine) and its effect on platelet adenosine uptake in man. Eur J Clin Pharmacol. 1982;23(3):229-34. doi:10.1007/BF00547559; German DC, Kredich NM, Bjornsson TD. Oral dipyridamole increases plasma adenosine levels in human beings. Clin Pharmacol Ther. 1989 Jan;45(1):80-4. doi:10.1038/clpt.1989.12; Kerndt CC, Nagalli S. Dipyridamole. 2021. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.2021 Nov 25.; Карева ЕН. Особенности фармакологического действия и применения дипиридамола в профилактике и лечении вирусных инфекций. Consilium Medicum. 2016;18(12):80-7. doi:10.26442/2075-1753_2016.12.80-87; Kim JA, Tran ND, Zhou W, Fisher M. Dipyridamole enhances tissue plasminogen activator release by brain capillary endothelial cells. Thromb Res. 2005;115(5):435-8. doi:10.1016/j.thromres.2004.10.001. Epub 2004 Nov 5.; Costantini V, Talpacci A, Bastiano ML, et al. Increased prostacyclin production from human veins by dipyridamole: an in vitro and ex vivo study. Biomed Biochim Acta. 1990;49(4):263-71.; Long Y, Xia JY, Chen SW, et al. ATP2B1 gene Silencing Increases Insulin Sensitivity through Facilitating Akt Activation via the Ca2+/calmodulin Signaling Pathway and Ca2+-associated eNOS Activation in Endothelial Cells. Int J Biol Sci. 2017 Sep 5;13(9):1203-12. doi:10.7150/ijbs.19666. eCollection 2017.; Pirahanchi Y, Dimri M. Biochemistry, Guanylate Cyclase. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.2021 Jul 22.; Kim HH, Liao JK. Translational therapeutics of dipyridamole. Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s39-42. doi:10.1161/ATVBAHA.107.160226. Epub 2008 Jan 3.; Chakrabarti S, Vitseva O, Iyu D, et al. The effect of dipyridamole on vascular cellderived reactive oxygen species. J Pharmacol Exp Ther. 2005 Nov;315(2):494-500. doi:10.1124/jpet.105.089987. Epub 2005 Jul 2.; European Stroke Prevention Study. ESPS Group. Stroke. 1990 Aug;21(8):1122-30. doi:10.1161/01.str.21.8.1122; Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996 Nov;143(1-2):1-13. doi:10.1016/s0022-510x(96)00308-5; ESPRIT Study Group; Halkes PH, van Gijn J, Kappelle LJ, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet. 2006 May 20;367(9523):1665-73. doi:10.1016/S0140-6736(06)68734-5; Diener HC, Sacco RL, Yusuf S, et al; Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008 Oct;7(10):875-84. doi:10.1016/S1474-4422(08)70198-4. Epub 2008 Aug 29.; Sacco RL, Diener HC, Yusuf S, et al; PRoFESS Study Group. Aspirin and extendedrelease dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008 Sep 18;359(12):1238-51. doi:10.1056/NEJMoa0805002. Epub 2008 Aug 27.; Weintraub WS. The vascular effects of cilostazol. Can J Cardiol. 2006 Feb;22 Suppl B(Suppl B):56B-60B. doi:10.1016/s0828-282x(06)70987-4; Tornyos D, Balint A, Kupo P, et al. Antithrombotic Therapy for Secondary Prevention in Patients with Non-Cardioembolic Stroke or Transient Ischemic Attack: A Systematic Review. Life (Basel). 2021 May 15;11(5):447. doi:10.3390/life11050447; Albay CEQ, Leyson FGD, Cheng FC. Dual versus mono antiplatelet therapy for acute non-cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis – updated meta-analysis. BMC Neurol. 2020 Jun 3;20(1):224. doi:10.1186/s12883-020-01808-y; Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019 Dec;50(12):e344-e418. doi:10.1161/STR.0000000000000211. Epub 2019 Oct 30.; Rahman H, Khan SU, Nasir F, et al. Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack. Stroke. 2019 Apr;50(4):947-53. doi:10.1161/STROKEAHA.118.023978; Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi:10.1161/STR.0000000000000375. Epub 2021 May 24.
-
2Academic Journal
Συγγραφείς: A. V. Fonyakin, L. A. Geraskina, M. Yu. Maksimova, А. В. Фонякин, Л. А. Гераскина, М. Ю. Максимова
Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 13, No 5 (2021); 14-19 ; Неврология, нейропсихиатрия, психосоматика; Vol 13, No 5 (2021); 14-19 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2021-5
Θεματικοί όροι: вторичная профилактика, transient ischemic attack, noncardioembolic stroke, secondary prevention, транзиторная ишемическая атака, некардиоэмболический инсульт
Περιγραφή αρχείου: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1660/1304; Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. Stroke. 2009 Jun;40(6):2276-93. doi:10.1161/STROKEAHA.108.192218. Epub 2009 May 7.; Стаховская ЛВ, редактор. Клинические рекомендации по ведению больных с ишемическим инсультом и транзиторными ишемическими атаками. Москва: МЕДпресс-информ; 2017. 208 с.; Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of transient ischemic attack. JAMA. 2000 Dec 13;284(22):2901-6. doi:10.1001/jama.284.22.2901; Johnston SC, Nguyen-Huynh MN, Schwarz ME, et al. National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol. 2006 Sep;60(3):301-13. doi:10.1002/ana.20942; European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25(5):457-507. doi:10.1159/000131083. Epub 2008 May 6.; Гераскина ЛА, Фонякин АВ. Транзиторные ишемические атаки. Современный взгляд на актуальную проблему. Трудный пациент. 2011;(5):28-32.; Rothwell PM, Giles MF, Flossmann E, et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet. 2005 Jul 2-8;366(9479):29-36. doi:10.1016/S0140-6736(05)66702-5; Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007 Jan 27;369(9558):283-92. doi:10.1016/S0140-6736(07)60150-0; Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46-e110. doi:10.1161/STR.0000000000000158. Epub 2018 Jan 24.; Суслина ЗА, Фонякин АВ, Кузнецов АЛ. Кардиоэмболический инсульт: источники эмболии и пути профилактики. Атмосфера. Новости кардиологии. 2004;(2):13-6.; Purroy F, Montaner J, Molina CA, et al. Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. Stroke. 2007 Dec;38(12):3225-9. doi:10.1161/STROKEAHA.107.488833; Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi:10.1161/STR.0000000000000375; Naqvi IA, Kamal AK, Rehman H. Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2020 Aug 17;8(8):CD009716. doi:10.1002/14651858.CD009716.pub2; Chimowitz MI, Lynn MJ, Howlett-Smith H, et al; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005 Mar 31;352(13):1305-16. doi:10.1056/NEJMoa043033; Chimowitz MI, Lynn MJ, Derdeyn CP, et al; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011 Sep 15;365(11):993-1003. doi:10.1056/NEJMoa1105335. Epub 2011 Sep 7.; Collaborative overview of randomised trials of antiplatelet therapy: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994 Jan 8;308(6921):81-106.; Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324(7329):71-86. doi:10.1136/bmj.324.7329.71; He J, Whelton P, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998 Dec 9;280(22):1930-5. doi:10.1001/jama.280.22.1930; Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Med. 2016 Jul 7;375(1):35-43. doi:10.1056/NEJMoa1603060. Epub 2016 May 10.; Amarenco P, Albers GW, Denison H, et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16:301-10. doi:10.1016/S1474-4422(17)30038-8; CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996 Nov 16;348(9038):1329-39. doi:10.1016/s0140-6736(96)09457-3; Costa J, Ferro JM, Matias-Guiu J, et al. Trifluzal for preventing serious vascular events in people at high risk. Stroke. 2005 Jul 20;(3):CD004296. doi:10.1002/14651858.CD004296.pub2; Huang Y, Cheng Y, Wu J, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomized double blind pilot study. Lancet Neurol. 2008 Jun;7(6):494-9. doi:10.1016/S1474-4422(08)70094-2. Epub 2008 May 2.; Shinohara Y, Nishimaru K, Sawada T, et al. Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS). Stroke. 2008 Jun;39(6):1827-33. doi:10.1161/STROKEAHA.107.505131. Epub 2008 Apr 3.; Kennedy J, Ryckborst KJ, Eliasziw M, et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomized controlled pilot trial. Lancet Neurol. 2007 Nov;6(11):961-9. doi:10.1016/S1474-4422(07)70250-8. Epub 2007 Oct 10.; Rothwell PM, Giles MF, Chandratheva A, et al. Effect of urgent treatment of transient ischemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet. 2007 Oct 20;370(9596):1432-42. doi:10.1016/S0140-6736(07)61448-2; Танашян ММ, Домашенко МА. Применение курантила при цереброваскулярных заболеваниях. Атмосфера. Нервные болезни. 2005;(3):8-11.; Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2 (ESPS2). Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996 Nov;143(1-2):1-13. doi:10.1016/s0022-510x(96)00308-5; ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, et al. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol. 2007 Feb;6(2):115-24. doi:10.1016/S1474-4422(06)70685-8; Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a metaanalysis. Stroke. 2008;39(4):1358-63. doi:10.1161/STROKEAHA.107.496281; Guiraud-Chaumeil B, Rascol A, David J, et al. Prevention des recidives des accidents vasculaires cerebraux ischemiques par les antiagregants plaquettaires: resultants d'un essai therapique controle de 3 ans. Rev Neurol. 1982;138(5):367-85.; Bousser MG, Eschwege E, Haguenau M, et al. «AICLA» controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke. Jan-Feb 1983;14(1):5-14. doi:10.1161/01.str.14.1.5; American-Canadian Cooperative Study Group. Persantine aspirin trial in cerebral ischemia, part II: endpoint results. Stroke. May-Jun 1985;16(3):406-15. doi:10.1161/01.str.16.3.406; Johnston SC, Easton JD, Farrant M, et al.; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018 Jul 19;379(3):215-25. doi:10.1056/NEJMoa1800410. Epub 2018 May 16.; Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013 Jul 4;369(1):11-9. doi:10.1056/NEJMoa1215340. Epub 2013 Jun 26.; Ge F, Lin H, Liu Y, et al. Dual antiplatelet therapy after stroke or transient ischaemic attack – how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. Eur J Neurol. 2016 Jun;23(6):1051-7. doi:10.1111/ene.12982. Epub 2016 Mar 28.; Johnston SC, Amarenco P, Denison H, et al; THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020 Jul 16;383(3):207-17. doi:10.1056/NEJMoa1916870
-
3Academic Journal
Συγγραφείς: I. S. Yavelov, E. Yu. Okshina, И. С. Явелов, Е. Ю. Окшина
Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 11, No 3S (2019): Спецвыпуск: когнитивные нарушения, цереброваскулярные заболевания; 78-81 ; Неврология, нейропсихиатрия, психосоматика; Vol 11, No 3S (2019): Спецвыпуск: когнитивные нарушения, цереброваскулярные заболевания; 78-81 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2019-3S
Θεματικοί όροι: ацетилсалициловая кислота, ischemic stroke, non-cardioembolic stroke, atherothrombotic stroke, atrial fibrillation, oral anticoagulants, acetylsalicylic acid, ишемический инсульт, некардиоэмболический инсульт, атеротромботический инсульт, фибрилляция предсердий, пероральные антикоагулянты
Περιγραφή αρχείου: application/pdf
Relation: https://nnp.ima-press.net/nnp/article/view/1137/918; Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-962. doi:10.1093/eurheartj/ehw210; January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. JACC. 2019. doi:10.1016/j.jacc.2019.01.011; Kim YD, Cha MJ, Kim J, et al. Increases in cerebral atherosclerosis according to CHADS2 scores in patients with stroke with nonvalvular atrial fibrillation. Stroke. 2011;42:930-4. doi:10.1161/STROKEAHA.110.602987; Arboix A, Garcia-Eroles L, Massons JB, et al. Atrial fibrillation and stroke: clinical presentation of cardioembolic versus atherothrombotic infarction. Int J Cardiol. 2000;73:33-42. doi:10.1016/S0167-5273(99)00214-4; Benbir G, Uluduz D, Ince B, Bozluolcay M. Atherothrombotic ischemic stroke in patients with atrial fibrillation. Clin Neurol Neurosurg. 2007;109:485-90. doi:10.1016/j.clineuro.2007. 03.009; Bogousslavsky J, van Melle G, Regli F, Kappenberger L. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry. Neurology. 1990;40:1046-50. doi:10.1212/WNL.40.7.1046; Hart RG, Pearce LA, Miller VT, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis. 2000;10:39-43. doi:10.1159/000016023; Chang YJ, Ryu SJ, Lin SK. Carotid artery stenosis in ischemic stroke patients with nonvalvular atrial fibrillation. Cerebrovasc Dis. 2002; 13:16-20. doi:10.1159/000047740; Park YS, Chung PW, Kim YB, et al. Small deep infarction in patients with atrial fibrillation: evidence of lacunar pathogenesis. Cerebrovasc Dis. 2013;36:205-10. doi:10.1159/000353736; Evans A, Perez I, Yu G, Kalra L. Secondary stroke prevention in atrial fibrillation: lessons from clinical practice. Stroke. 2000;31:2106-11. doi:10.1161/01.STR.31.9.2106; Evans A, Perez I, Yu G, Kalra L. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? Stroke. 2001;32:2828-32. doi:10.1161/hs1201.099520; Katsi V, Georgiopoulos G, Skafida A, et al. Noncardioembolic stroke in patients with atrial fibrillation. Angiology. 2019;70:299-304. doi:10.1177/0003319718791711; Cano LM, Cardona P, Quesada H, et al. Ischaemic stroke in patients treated with oral anticoagulants. Neurologia. 2016;31:395-400. doi:10.1016/j.nrl.2014.09.010; Hwang J, Chung J-W, Lee MJ, et al. Implications of CHA2DS2-VASc Score in Stroke Patients with Atrial Fibrillation: An Analysis of 938 Korean Patients. Eur Neurol. 2017;77:307- 15. doi:10.1159/000475495; Kim SJ, Ryoo S, Kwon S, et al. Is atrial fibrillation always a culprit of stroke inpatients with atrial fibrillation plus stroke? Cerebrovasc Dis. 2013;36:373-82. doi:10.1159/000355571; Cha M-J, Kim YD, Nam HS, et al. Stroke mechanism in patients with non-valvular atrial fibrillation according to the CHADS2 and CHA2DS2-VASc scores. Eur J Neurol. 2012; 19:473-9. doi:10.1111/j.1468-1331.2011.03547.x; Yang P-S, Pak H-N, Park D-H, et al. Noncardioembolic risk factors in atrial fibrillationassociated ischemic stroke. PLoS ONE. 2018; 13:e0201062. doi:10.1371/journal.pone.0201062; Bekwelem W, Jensen PN, Norby FL, et al. Carotid atherosclerosis and stroke in atrial fibrillation: the atherosclerosis risk in Communities study. Stroke. 2016;47:1643-46. doi:10.1161/STROKEAHA.116.013133; Paciaroni M, Agnelli G, Ageno W, et al. Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. Atherosclerosis. 2010;212:564-6. doi:10.1016/j.atherosclerosis.2010.06.016; Miller VT, Pearce LA, Feinberg WM, et al. Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke prevention in atrial fibrillation investigators. Neurology. 1996;46:238-40. doi:10.1212/WNL.46.1.238; Becattini C, Dentali F, Camporese G, et al. Carotid atherosclerosis and risk for ischemic stroke in patients with atrial fibrillation on oral anticoagulant treatment. Atherosclerosis. 2018; 271:177-81. doi:10.1016/j.atherosclerosis.2018.02.004; Lane DA, Raichand S, Moore D, et al. Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review. Health Technol Assess. 2013; 17(30). doi:10.3310/hta17300; Kumar S, Danik SB, Altman RK, et al. NonVKA Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients with Atrial Fibrillation: a Meta-analysis of Randomized Controlled Trials. Cardiol Rev. 2016;24: 218-23. doi:10.1097/CRD.0000000000000088; Masunaga N, Abe M, Ogawa H, et al. Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation. The Fushimi AF Registry. Circ J. 2018;82:2983-91. doi:10.1253/circj.CJ-18-0872; Steinberg BA, Kim S, Piccini JP, et al. Use and Associated Risks of Concomitant Aspirin Therapy with Oral Anticoagulation in Patients with Atrial Fibrillation: Insights from the ORBIT-AF Registry. Circulation. 2013;128:721-8. doi:10.1161/CIRCULATIONAHA.113.002927; Olesen JB, Lip GYH, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost. 2011;106:739-49. doi:10.1160/TH11-05-0364; Nakamura A, Kuroda J, Ago T, et al. Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation. Cerebrovasc Dis. 2016;42: 196-204. doi:10.1159/000445723; Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. NEJM. 2017;377:1319-30. doi:10.1056/NEJMoa1709118; Sharma M, Hart RG, Connolly SJ, et al. Stroke Outcomes in the COMPASS Trial. Circulation. 2019;139:1134-45. doi:10.1161/ CIRCULATIONAHA.118.035864
-
4Academic Journal
Συγγραφείς: A. V. Fonyakin, L. A. Geraskina, А. В. Фонякин, Л. А. Гераскина
Πηγή: Aterotromboz = Atherothrombosis; № 1 (2017); 123-133 ; Атеротромбоз; № 1 (2017); 123-133 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2017-1
Θεματικοί όροι: вторичная профилактика, ischemic non-cardioembolic stroke, secondary prevention, ишемический некардиоэмболический инсульт
Περιγραφή αρχείου: application/pdf
Relation: https://www.aterotromboz.ru/jour/article/view/115/159; Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack. A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke, 2014, 45: 2160-2236.; Суслина З.А., Фонякин А.В., Кузнецов А.Л. Кардио-эмболический инсульт: источники эмболии и пути профилактики. Атмосфера. Новости кардиологии, 2004, 2: 13-16.; Гераскина Л.А., Фонякин А.В., Суслина З.А. Артериальная гипертония и гетерогенность ишемического инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова. Инсульт. Приложение, 2003, 9: 138.; Суслина З.А., Фонякин А.В., Гераскина Л.А., Шандалин В.А. Кардионеврология. Справочное руководство с обзором клинических исследований. Под редакцией З.А. Суслиной и А.В. Фонякина М., 2011.; Olsson JE, Brechter C, Backlund H et al. Anticoagulant vs anti-platelet therapy as prophylactic against cerebral infarction in transient ischemic attacks. Stroke, 1980, 11: 4–9.; The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol, 1997, 42: 857–865.; Chimowitz MI, Lynn MJ, Howlett-Smith H et al, for the Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med, 2005, 352: 1305–1316.; The ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ et al. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomized controlled trial. Lancet Neurol, 2007, 6: 115–124.; De Schryver EL, Algra A, Kappelle LJ et al. Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin. Cochrane Database Syst Rev, 2012, 9: CD001342.; Antithrombotic Tralists` Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ, 2002, 324: 71-86.; Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of Patients. BMJ, 1994, 308: 81–106.; He J, Whelton P, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA, 1998, 280: 1930–1935.; Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study 2 (ESPS2). Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci, 1996, 143: 1-13.; Gent M, Blakely JA, Easton JD et al. The Canadian American Ticlopidin Study (CATS) in thromboembolic stroke. Lancet, 1989, 1: 1215-1220.; Hass WK, Easton JD, Adams HP et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidin Aspirin Stroke Study Group. N Engl J Med, 1989, 321: 501-507.; Gorelick PB, Richardson D, Kelly M et al, for the African American Antiplatelet Stroke Prevention Study Investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a ran-domized trial. JAMA, 2003, 289: 2947-2957.; CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet, 1996, 348: 1329-1339.; Танашян М.М., Умарова Р.М., Гераскина Л.А., Фонякин А.В. Гемангиокорректорная эффективность Плавикса у больных с церебральной ишемией. Нервные болезни, 2005, 3: 2-7.; Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet, 2004, 364: 331-337.; Bhatt DL, Fox KAA, Hacke W et al. CHARISMA investigators: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med, 2006, 354: 1706-1717.; Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol, 2007, 49: 1982-1988.; SPS3 Investigators, Benavente OR, Hart RG, McClure LA et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med, 2012, 367: 817-825.; Kennedy J, Ryckborst KJ, Eliasziw M et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomized controlled pilot trial. Lancet Neurol, 2007, 6: 961–969.; Zuo F-T, Liu H, Wu H-J. The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese Patients A randomized and controlled trail. Medicine, 2017, 96: 1-6 (e5497).; Wang Y, Wang Y, Zhao X et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med, 2013, 369: 11-9.; Xie W, Zheng F, Zhong B, Song X. Long-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-Analysis. J Am Heart Assoc, 2015, 4: 2-15. e002259.; Koziol K, Van der Merwe V, Yakiwchuk E, Kosar L. Dual antiplatelet therapy for secondary stroke prevention Use of clopidogrel and acetylsalicylic acid after noncardioembolic ischemic stroke. Canadian Family Physician, 2016, 62: 640-645.; Ge F, Lin H, Liu Y, Li M et al. Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. Eur J Neurol, 2016, 23: 1051-1057.; The ESPS Group. The European Stroke Prevention Study (ESPS): principal end-points. Lancet, 1987, 2: 1351–1354.; The ESPRIT study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet, 2006, 367: 1665-1673.; Diener HC, Sacco RL, Yusuf S, Steering Committee of PROFESS Study Group: Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two Antithrombotic regimen (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with stroke. The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PROFESS). Cerebrovasc Dis, 2007, 23: 368–380.; Costa J, Ferro JM, Matias-Guiu J et al. Trifluzal for preventing serious vascular events in people at high risk. Stroke, 2006, 37, 2193-2195.; Huang Y, Cheng Y, Wu J et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a random-ized double blind pilot study. Lancet Neurol, 2008, 7: 494-499.; Shinohara Y, Katayama Y, Uchiyama S et al, CSPS 2 Group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol, 2010, 9: 959–968.; Shinohara Y, Nishimaru K, Sawada T et al. Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS). Stroke, 2008, 39: 1827-1833.; Johnston SC, Amarenco P, Albers GW et al. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. N Engl J Med, 2016, 375: 35-43.; Amarenco P, Albers GW, Denison H et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol, 2017, 16: 301-310.; https://www.aterotromboz.ru/jour/article/view/115